OneThree Biotech raises seed round for AI-driven drug platform

Photos by: Dom Guzman

Drug development is a famously slow process. One key reason is that even if researchers find a therapy effective in treating an illness, they must still complete extensive tests to rule out harmful side effects.

OneThree Biotech is hoping to speed up the timeline for drug developers. The New York-based startup is building an artificial intelligence platform for use in drug discovery and development that aims to identify promising targets as well as potential risks and side effects at an early stage.

As researchers pour resources into finding drugs to treat COVID-19, the company has started offering free toxicity screening on potential treatments for the virus.

[Read the rest on Crunchbase News]